| Literature DB >> 32369032 |
Jennifer Dacey Allen1, Amanda Reich1, Adolfo G Cuevas1, Keren Ladin1.
Abstract
BACKGROUND: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate-specific antigen (PSA) screening test has a high risk of false-positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks.Entities:
Keywords: decision making (shared); decision support techniques; early detection of cancer; men’s health; minority health; prostate neoplasms
Mesh:
Substances:
Year: 2020 PMID: 32369032 PMCID: PMC7238086 DOI: 10.2196/15502
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Sample of Ottawa Decision Support Framework constructs, content, and format addressed in Prostate Cancer Screening Preparation decision aid.
| Construct | Prostate Cancer Screening Preparation content | Format/presentation |
| Knowledge |
Factual information about prostate cancer incidence and mortality among African American men; potential benefits, risks, and harms of PSAa screening; methods for diagnosing and treating prostate cancer, etc. Users are provided access to a section that assesses individual risk based on the risk factor information input by the user. |
Video: Doctors presenting information modeled after a popular television show. Fictionalized audience members “call in” to pose questions, which are subsequently answered by the doctors. Thermometer indicates risk relative to other men of the same age (ie, greater than, similar to, or less than average). |
| Decision self-efficacy |
Users are led through decision-making steps specified by the Ottawa Decision Support Framework, including identifying options, addressing information needs, and clarifying values. |
On-screen text with one page per step. |
| Clarification of values |
Consideration of the potential advantages and disadvantages of PSA screening. |
Users presented with common “pros” and “cons,” which are rated by users. |
aPSA: prostate-specific antigen.
Figure 1The Check-Up Show.
Figure 2Individualized Risk Assessment.
Characteristics of study participants in the Prostate Cancer Screening Preparation pilot study (n=41).
| Characteristics | Value, n (%)a | |
|
| ||
|
| 45-54 | 16 (43) |
|
| 55-64 | 15 (41) |
|
| 65-70 | 6 (16) |
|
| ||
|
| Less than $25,000 | 12 (29) |
|
| $25,000-$49,999 | 8 (20) |
|
| $50,000-$74,999 | 13 (31) |
|
| More than $75,000 | 8 (19) |
|
| ||
|
| Not married | 21 (51) |
|
| Married/living as married | 20 (49) |
|
| ||
|
| Less than high school | 2 (5) |
|
| Some college or 2-year degree | 10 (23) |
|
| 4-year college degree | 17 (41) |
|
| More than a 4-year college degree | 12 (29) |
|
| ||
|
| Yes | 35(85) |
|
| ||
|
| Very good/good | 24 (59) |
|
| Fair/poor | 17 (41) |
aTotal varies because of missing responses; percentages may not total to 100% because of rounding.
Changes in informed decision-making outcomes from pretest to posttest in the Prostate Cancer Screening Preparation pilot study (n=41).
| Informed decision-making outcomes | Internal reliability Cronbach alpha | Pretest, mean (SD) | Posttest, mean (SD) | Change, | Effect size | |
| Knowledge (0-100) | .77 | 49.45 (21.52) | 61.94 (19.97) |
| 0.56 |
|
| Decision self-efficacy (0-100) | .90 | 86.12 (18.60) | 88.51 (16.89) | .84 | N/Ab |
|
| Decisional Conflict Scale ( | .86 | 23.8 (26.6) | 14.8 (19.52) |
| −0.44 |
|
| Value of screening (0-100) | .75 | 75.7 (13.96) | 70.67 (15.73) |
| −0.38 |
|
aP<.05.
bN/A: not applicable.